Concord Biotech Intrinsic Value
Concord Biotech (CONCORDBIO) median intrinsic value is ₹2480.00 from 9 valuation models (range ₹401–₹3344), vs current price ₹1337.60 — +85.4% upside (Trading Below Calculated Value), margin of safety 46.1%. Browse CONCORDBIO cash flow statement for revenue, profit, balance sheet and cash flow data.
CONCORDBIO Valuation Methods Summary — DCF, Graham Number & P/E
Concord Biotech intrinsic value across 9 models vs current price ₹1337.60 — upside/downside and value range per method. Also explore Concord Biotech stock price data download to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹744.48 | ₹595.58 - ₹893.38 | -44.3% | EPS: ₹33.84, Sector P/E: 22x |
| Book Value Method | asset | ₹3344.00 | ₹3009.60 - ₹3678.40 | +150.0% | Book Value/Share: ₹1833.64, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹2480.00 | ₹2232.00 - ₹2728.00 | +85.4% | Revenue/Share: ₹1240.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2675.20 | ₹2407.68 - ₹2942.72 | +100.0% | EBITDA: ₹536.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹2512.59 | ₹2010.07 - ₹3015.11 | +87.8% | CF Growth: 10.1%, Discount: 15% |
| PEG Ratio Method | growth | ₹401.28 | ₹361.15 - ₹441.41 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹522.83 | ₹470.55 - ₹575.11 | -60.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹2675.20 | ₹2407.68 - ₹2942.72 | +100.0% | ROE: 17.6%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹1181.58 | ₹1063.42 - ₹1299.74 | -11.7% | EPS: ₹33.84, BVPS: ₹1833.64 |
CONCORDBIO Intrinsic Value vs Market Price — All Valuation Models
Concord Biotech fair value range ₹401–₹3344 vs current market price ₹1337.60 across 9 valuation models. For current market price and key ratios, visit Concord Biotech stock price NSE.
CONCORDBIO Intrinsic Value Analysis — Undervalued or Overvalued?
Concord Biotech median intrinsic value ₹2480.00, current price ₹1337.60 — Trading Below Calculated Value by 85.4%, margin of safety 46.1%.
What is the intrinsic value of CONCORDBIO?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Concord Biotech (CONCORDBIO) is ₹2480.00 (median value). With the current market price of ₹1337.60, this represents a +85.4% variance from our estimated fair value.
The valuation range spans from ₹401.28 to ₹3344.00, indicating ₹401.28 - ₹3344.00.
Is CONCORDBIO undervalued or overvalued?
Based on our multi-method analysis, Concord Biotech (CONCORDBIO) appears to be trading below calculated value by approximately 85.4%.
CONCORDBIO Financial Health — Key Ratios vs Industry Benchmarks
Concord Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 24.51 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 17.6% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 36.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.61x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
CONCORDBIO Cash Flow Quality — Operating & Free Cash Flow
Concord Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹245 Cr | ₹165 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹266 Cr | ₹189 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹246 Cr | ₹167 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹208 Cr | ₹152 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹167 Cr | ₹70 Cr | Positive Free Cash Flow | 7/10 |